Here's the strange detail about ipamorelin: it activates the same receptor as ghrelin, the hormone your stomach releases when it's empty. The compound is sold for research use only and isn't approved by any regulator for medical purposes, but it has been a fixture of selective-secretagogue pharmacology since the late 1990s. This article walks through what ipamorelin is at the chemical level, how its receptor works, why a single in-vitro selectivity result made it interesting to endocrinology labs, and how it sits next to other peptides on the growth-hormone axis. Research-grade material is not equivalent to any FDA-approved pharmaceutical product, and no pharmaceutical product carries this name.
What Ipamorelin Is — Sequence, Origin, and Chemistry
What this section tells you: ipamorelin is a five-amino-acid synthetic peptide built by Danish medicinal chemists in the late 1990s as part of a search for cleaner growth-hormone secretagogues.
Structurally, ipamorelin is a pentapeptide with the sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2. Its molecular formula is C38H49N9O5, its molar mass is roughly 712 g/mol, and its CAS number is 170851-70-4. The compound was developed at Novo Nordisk under the code NNC 26-0161, derived from the older growth hormone-releasing peptide GHRP-1 by stripping out the central Ala-Trp dipeptide — a deliberate edit that, as the chemistry team would later confirm, was responsible for the cleaner pharmacology that distinguishes it from earlier compounds in the family.
Several of the building blocks are unusual. The N-terminal aminoisobutyric acid (Aib) is a non-natural amino acid that resists enzymatic cleavage. The two D-amino acids — D-2-naphthylalanine and D-phenylalanine — flip the stereochemistry of those residues, again giving the molecule metabolic stability that a straight L-peptide of the same sequence would lack. The C-terminal amide caps the carboxyl end against carboxypeptidases. Net effect: a small, stable peptide whose geometry slots into the hydrophobic pocket that the ghrelin receptor uses to recognize its endogenous ligand.
The pharmacokinetics observed in research models match that engineering — an elimination half-life of roughly two hours and no oral bioavailability in standard formulations. For readers who want a similar level of structural detail on a different peptide in the same product category, see our TB-500 chemical structure article.
How the Ghrelin Receptor Works — The "Hunger Hormone" Receptor Explained
What this section tells you: the receptor ipamorelin engages is the same one your gut talks to when you're hungry, and the selectivity story only makes sense once you understand the receptor's biology.
What ghrelin actually is
Ghrelin is a 28-amino-acid peptide produced mainly by P/D1 cells in the lining of the stomach. Plasma ghrelin rises before meals and falls after them, which is how it picked up the popular nickname "the hunger hormone." Ghrelin is also unusual among peptide hormones: it carries a post-translational n-octanoyl modification on its third serine residue — an eight-carbon fatty-acid tail installed by a single dedicated enzyme called ghrelin-O-acyltransferase, or GOAT. Without that octanoyl tail, des-acyl ghrelin doesn't activate the receptor, which is one of the more striking examples in peptide biology of a small chemical modification governing an entire signaling axis.
The receptor itself: GHS-R1a
The growth hormone secretagogue receptor 1a (GHS-R1a) is a Class A G-protein-coupled receptor. When ghrelin engages it, the receptor couples preferentially to Gαq, which activates phospholipase C, generates inositol trisphosphate (IP3), and releases calcium from intracellular stores. Downstream of that first event, the receptor recruits a cascade of kinases — MAPK, PKA, PKB/AKT, AMPK — each carrying the signal into different cellular programs depending on the tissue. Cryo-EM structures published in 2021 resolved how the octanoyl chain inserts into a hydrophobic pocket between transmembrane helices 6 and 7, explaining at the atomic level why acylation is non-negotiable for the natural ligand and why synthetic agonists like ipamorelin work by engaging the same pocket directly.
Where the receptor lives in the body
GHS-R1a isn't a single-tissue receptor. It's expressed at high levels in the pituitary, where its activation triggers growth-hormone secretion, and it's also abundant in the hypothalamus — specifically the ventromedial and arcuate nuclei that govern appetite and energy balance. Outside those classical sites, the receptor turns up in the hippocampus (where research models link it to learning and long-term potentiation), the ventral tegmental area (reward circuitry), the liver, skeletal muscle, and even cardiomyocytes. That wide distribution is why the ghrelin axis touches so many physiological systems at once — hunger, growth, reward, memory, peripheral metabolism — and why interpreting any compound that engages this receptor means keeping the full anatomy in mind.
A pharmacologically unusual feature: constitutive activity
GHS-R1a is one of the most constitutively active GPCRs known. Put plainly: the receptor produces a tonic signal even when no ghrelin is bound — it's partially "on" by default. Genetic work has shown that loss-of-constitutive-activity variants are linked to familial short stature, indicating that this baseline output is functionally important for normal growth. More recently, liver-expressed antimicrobial peptide-2 (LEAP-2) was identified as an endogenous inverse agonist of GHS-R1a — a counter-regulatory tone the body uses to dampen the receptor's baseline signaling. For research models exposed to a synthetic agonist like ipamorelin, this constitutive baseline is the reason growth-hormone pulses still occur between exposures, and the reason simple occupancy models don't capture the full pharmacology.